


RealRate

PHARMACEUTICAL 2019

## RENOVARO BIOSCIENCES INC. Rank 37 of 363







PHARMACEUTICAL 2019

## RealRate

## RENOVARO BIOSCIENCES INC. Rank 37 of 363

The relative strengths and weaknesses of RENOVARO BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RENOVARO BIOSCIENCES INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 271% points. The greatest weakness of RENOVARO BIOSCIENCES INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 218% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	15,762
Cost of Goods Sold	0
Intangible Assets	163,735
Liabilities, Current	874
Liabilities, Non-Current	0
Other Assets	138
Other Compr. Net Income	0
Other Expenses	3,799
Other Liabilities	22,891
Other Net Income	-1,094
Other Revenues	0
Property and Equipment	27
Research and Development	617
Selling, General and Administrative Expense	3,642

Output Variable	Value in 1000 USD
Assets	179,662
Liabilities	23,765
Expenses	8,058
Revenues	0
Stockholders Equity	155,898
Net Income	-9,152
Comprehensive Net Income	-9,152
Economic Capital Ratio	255%

